Susanne Saußele
A5013024565- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Fungal Plant Pathogen Control
- Click Chemistry and Applications
- Retinoids in leukemia and cellular processes
- Advanced biosensing and bioanalysis techniques
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Quinazolinone synthesis and applications
- Immune Cell Function and Interaction
- Gastric Cancer Management and Outcomes
- Cytokine Signaling Pathways and Interactions
- Ferrocene Chemistry and Applications
- Mast cells and histamine
- HIV/AIDS drug development and treatment
- Gastrointestinal Tumor Research and Treatment
- Peptidase Inhibition and Analysis
University Hospital Heidelberg
2015-2024
Heidelberg University
2015-2024
Medizinische Fakultät Mannheim
2015-2024
University Medical Centre Mannheim
2008-2024
University of Mannheim
2018-2024
Heidelberg University
1998-2023
South Australia Pathology
2019
Institut Bergonié
2017
Johns Hopkins University
2016
Inserm
2016
Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400 mg/d can be unsatisfactory. Optimization treatment is warranted.In all, 1,014 newly diagnosed CP-CML patients were randomly assigned to 800 (n = 338), 325), or plus interferon alfa (IFN-α; n 351). Dose adaptation avoid higher-grade toxicity was recommended. First primary end point major molecular remission (MMR) at 12 months.A higher rate MMR months occurred tolerability-adapted than (59% [95% CI, 53% 65%] v 44%...
Deep molecular response (MR(4.5)) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after treatment discontinuation. It is unclear how many achieve MR(4.5) under different modalities and whether predicts survival.Patients from the randomized CML-Study IV were analyzed for confirmed which was defined as ≥ 4.5 log reduction BCR-ABL on international scale (IS) determined by reverse transcriptase polymerase chain reaction two consecutive...
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) using IM after IFN-failure (n=128). From July 2002 March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study powered detect survival difference of 5% 5 years. After median observation time 9.5 years, 10-year overall 82%,...
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in MR4.5 (BCR-ABL1⩽0.0032% on International Scale (BCR-ABL1IS)) and ⩾2 years of therapy were enrolled. sustained deep during 1-year consolidation eligible stop treatment enter TFR phase. loss major (MMR;...
Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse. In this multi-center, prospective clinical trial (EURO-SKI, NCT01596114) we analyzed function and phenotype T NK cells their relation to successful TKI cessation. Lymphocyte subclasses were measured from 100 imatinib-treated at baseline 1 month after discontinuation, functional characterization...
Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets ABL Myristoyl Pocket (STAMP), is approved worldwide for treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in phase (CML-CP) treated ≥2 prior tyrosine kinase inhibitors (TKIs). In ASCEMBL, patients CML-CP TKIs were randomized (stratified by baseline major cytogenetic response [MCyR]) 2:1 to asciminib 40 mg twice daily or bosutinib 500 once daily. Consistent previously published primary analysis...
ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis. Attempting TFR required ≥ 3 years of nilotinib, a molecular response MR4.5 [BCR-ABL1 ≤ 0.0032% on the International Scale (BCR-ABL1IS)], and sustained deep (DMR) during 1-year consolidation Patients restarted loss major (MMR; BCR-ABL1IS 0.1%). Ninety-six weeks...